Scancell Holdings Plc, (AIM:SCLP), the developer of therapeutic cancer vaccines, today announces the development of a new platform technology (Moditope) that stimulates the production of killer CD4 T cells with powerful anti-tumour activity. The Directors believe that this new discovery could have a profound effect on the way that cancer vaccines are developed. 

CD4 responses to cancer associated antigens have been notoriously difficult to generate whether presented as peptides, proteins or DNA. CD4 cells are vital for effective anti-tumour immunity. Scancell has identified and patented a series of modified epitopes that overcome this limitation. Scancell’s Moditope technology produces killer CD4 T cells that destroy tumours without toxicity 

Professor Lindy Durrant, Joint CEO of Scancell Holdings and Professor of Cancer Immunotherapy at Nottingham University, commented: “Not only do these unique epitopes stimulate a CD4 killer T cell response, we have also shown in tests that cancer patients can produce an immune response to these epitopes. The Moditope epitopes can be used to develop both DNA and peptide vaccines and could become an important component of many therapeutic vaccines in the future, both under development at Scancell and other companies” 

Prof Peter Stern, Head of the Cancer Research UK, Immunology Group at the Paterson Institute for Cancer Research, commented: “This novel technology has the potential to transform the therapeutic cancer field. It is increasingly recognised that combining products and technologies will unlock the full potential of cancer vaccines. The Moditope technology offers those developing cancer vaccines, a means to optimise the potency of their immune targets”. 

David Evans, Chairman of Scancell Holdings, commented: "This highly innovative discovery opens up a new approach to the development of cancer vaccines. Whilst currently at an early stage, we are aware that the opportunities could be considerable in addition to Scancell’s existing platform technology. As a result, the Board is actively evaluating its strategic options for this new technology platform and will be consulting with key shareholders in this regard. We are excited by the potential and are resolute in our aim of creating the greatest value for shareholders. The Board will update the market in due course.” 

The Directors of the issuer accept responsibility for this announcement. 

-ENDS-

For Further Information: